- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05445128
Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease
January 9, 2024 updated by: Ensoma
A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of MGTA-145 in Combination With Plerixafor for the Mobilization of Hematopoietic Stem Cells in Patients With Sickle Cell Disease
This research study is designed to investigate a new potential medicine for mobilizing stem cells and apheresis collection in patients with Sickle Cell Disease.
MGTA-145, the new potential medicine, will be given with plerixafor.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
This Phase 2, multicenter, open-label study will be conducted in 2 parts (Parts A and B).
Part A is intended to characterize the efficacy, safety, PK and PD of a single dose of MGTA-145 and plerixafor for HSC mobilization and apheresis collection in patients with SCD.
Part B is designed to characterize the efficacy, safety, PK and PD of 2 consecutive days of dosing with MGTA-145 and plerixafor for HSC mobilization and apheresis collection in patients with SCD.
Study Type
Interventional
Enrollment (Actual)
1
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Magenta Clinical Trials
- Phone Number: 857-242-0170
- Email: clinicaltrials@magentatx.com
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Boston Children's Hospital
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St. Jude Children's Research Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 35 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subject must be ≥18 to ≤35 years of age.
- Subject must weigh ≥30 kg.
- Subject must have a diagnosis of Sickle Cell Disease.
Exclusion Criteria:
- Subject must not have had a vaso-occlusive event (VOE) requiring a visit to a healthcare facility within 30 days of screening.
- Subject must not have undergone or attempted and failed previous hematopoietic stem cell (HSC) collection.
- Subject must not have had a prior autologous or allogeneic transplantation, inclusive of gene therapy.
- Male subject must be willing or able to use a highly effective method of contraception for 3 months during and after treatment.
- Female subject must not be pregnant or breastfeeding. If sexually active, female subject must be willing or able to use a highly effective method of contraception for 3 months during and after treatment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A: Single Day Dosing/Apheresis
Single dose of MGTA-145 in combination with plerixafor followed by apheresis
|
MGTA-145 will be administered as an IV infusion
240 µg/kg administered subcutaneously
|
Experimental: Part B: 2-Day Dosing/Apheresis
MGTA-145 in combination with plerixafor followed by apheresis on two consecutive days
|
MGTA-145 will be administered as an IV infusion
240 µg/kg administered subcutaneously
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Apheresis Collection Yield
Time Frame: Up to 2 days
|
Determination of the yield of CD34+ cells after either one or two consecutive days of MGTA-145 and plerixafor mobilization followed by apheresis.
|
Up to 2 days
|
Assess incidence of treatment emergent adverse events leading to study drug discontinuation based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Time Frame: Up to 30 days
|
Up to 30 days
|
|
Assess the incidence of treatment emergent >/= Grade 3 clinical laboratory abnormalities based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Time Frame: Up to 11 days
|
Up to 11 days
|
|
Vital Signs - Number of participants with clinically significant changes from baseline in vital signs
Time Frame: Up to 11 days
|
Up to 11 days
|
|
Laboratory Assessment - Number of participants with clinically significant changes from baseline in hematology and clinical chemistry laboratory parameters.
Time Frame: Up to 11 days
|
Up to 11 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mobilization Effects of single-day and two-day dosing with MGTA-145 and plerixafor in peripheral blood in patients with SCD
Time Frame: Up to 2 days
|
Determination of peak peripheral blood CD34+ counts
|
Up to 2 days
|
Investigate plasma concentrations of MGTA-145 per timepoint of collection (Pharmacokinetics)
Time Frame: Up to 2 days
|
Up to 2 days
|
|
Assess presence of MGTA-145 Anti-Drug Antibodies (ADA) in plasma samples (using electrochemiluminescent immunoassay [ECLIA])
Time Frame: Up to 11 days
|
Up to 11 days
|
|
Assess titers of MGTA-145 Anti-Drug Antibodies (ADA) in plasma samples (using electrochemiluminescent immunoassay [ECLIA])
Time Frame: Up to 11 days
|
Up to 11 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Ji Hyun Lee, MD, MPH, Magenta Therapeutics
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 24, 2022
Primary Completion (Actual)
December 8, 2022
Study Completion (Actual)
February 2, 2023
Study Registration Dates
First Submitted
May 26, 2022
First Submitted That Met QC Criteria
July 5, 2022
First Posted (Actual)
July 6, 2022
Study Record Updates
Last Update Posted (Actual)
January 11, 2024
Last Update Submitted That Met QC Criteria
January 9, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 145-SCD-204
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sickle Cell Disease
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
Nova Laboratories LimitedCompletedSickle Cell Disease | Sickle Cell Hemoglobin C | Sickle Cell-beta-thalassemia | Sickle-Cell; Hemoglobin Disease, ThalassemiaUnited Kingdom, Jamaica
-
SangartCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseUnited Kingdom, France, Jamaica, Lebanon
-
SangartWithdrawnSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseFrance, United Kingdom, Netherlands, Turkey, Bahrain, Belgium, Brazil, Lebanon, Qatar
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Heart, Lung, and Blood Institute (NHLBI)TerminatedSickle Cell Anemia | Sickle Cell-hemoglobin C Disease | Sickle Cell-β0-thalassemiaUnited States
-
University of RegensburgRecruitingSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | HbS Disease | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SGermany, Austria
-
Centre Hospitalier Intercommunal CreteilRecruitingSickle-Cell Disease Nos With CrisisFrance
-
HemaQuest Pharmaceuticals Inc.TerminatedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Egypt, Canada, Jamaica
-
HemaQuest Pharmaceuticals Inc.CompletedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Canada, Egypt, Jamaica
Clinical Trials on MGTA-145
-
EnsomaCompletedHealthy | Renal InsufficiencyUnited States
-
EnsomaNational Marrow Donor ProgramTerminatedAcute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Healthy Donors | Related Donors Donating PBSC to a Family MemberUnited States
-
EnsomaCompleted
-
Magenta Therapeutics, Inc.TerminatedAcute Myeloid Leukemia | MyelodysplasiaUnited States
-
Surbhi Sidana, MDCompletedMultiple MyelomaUnited States
-
Magenta Therapeutics, Inc.CompletedInherited Metabolic Disorders (IMD)United States
-
SecuraBioCompleted
-
SecuraBioCompletedAsthmaGermany, United Kingdom
-
SecuraBioCompletedHepatic ImpairmentUnited States
-
GE HealthcareMedpace, Inc.; Biomedical Systems; i3 Statprobe; Rules-Based Medicine, Inc.CompletedDiabete Mellitus | Congestive Heart Failure | Chronic Renal InsufficiencyUnited States